The ESMO presentation on October 23, 2026 will provide the first public disclosure of full OS data. Positive data could significantly increase the probability of accelerated approval for azenosertib in Cyclin E1-positive PROC, a large unmet need. Monitor for any safety signals or biomarker specificity concerns during the presentation.
Price Chart
Executive Summary
Zentalis announced positive overall survival data from an interim analysis of the DENALI Part 1b study for azenosertib in platinum-resistant ovarian cancer. The Cyclin E1-positive subgroup showed median OS of 15.8 months vs 7.5 months in the negative subgroup, with no new safety signals. These data support the ongoing Phase 3 ASPENOVA trial and the potential for accelerated approval, representing a significant clinical catalyst for this single-asset biotech.
Key Facts
- Median OS of 15.8 months in Cyclin E1-positive PROC patients (n=48) vs 7.5 months in Cyclin E1-negative (n=46)
- Data from interim analysis of DENALI Part 1b (GOG-3066) published as rapid oral presentation at ESMO Congress 2026 on October 23, 2026
- No new safety signals observed
- DENALI Part 2 enrollment complete; Part 2c enrolling; ASPENOVA Phase 3 confirmatory trial ongoing
- Cyclin E1-positive patients comprise approximately 50% of PROC patients with no currently approved targeted therapy
Financial Impact
Not stated in the filing; no revenue or financial projections provided
Risk Factors
- Data are from an interim analysis with small sample sizes (n=48 and n=46) and retrospective biomarker determination
- Accelerated approval requires positive Part 2 results and FDA alignment; full approval depends on ASPENOVA Phase 3 data
- Single-asset company risk — any clinical or regulatory setback would be highly material
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3382952 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 18, 2026 8d ago | Press Release | $2.30 | awaiting T+60 | — | $1.98 (−13.91%) |
Oct 1, 2026 25d ago | Press Release | $2.52 | awaiting T+60 | — | $1.98 (−21.43%) |
Aug 14, 2026 10w ago | 8-K | $3.71 | awaiting T+60 | — | $1.98 (+46.56%) |
Aug 13, 2026 10w ago | Press Release | $3.56 | awaiting T+60 | — | $1.98 (+44.38%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.75 $4.03 | ▲ +7.47% | ▲ +4.20% | $1.98 (−47.20%) |
Jun 1, 2026 21w ago | Press Release | $3.95 $3.89 | ▼ −1.52% | ▼ −2.64% | $1.98 (−49.87%) |
May 21, 2026 22w ago | Press Release | $4.06 $3.68 | ▼ −9.36% | ▼ −12.55% | $1.98 (−51.23%) |
May 21, 2026 22w ago | 8-K | $4.06 $3.68 | ▼ −9.36% | ▼ −12.55% | $1.98 (−51.23%) |
May 12, 2026 24w ago | 8-K | $4.28 $4.22 | ▼ −1.40% | ▼ −5.84% | $1.98 (−53.74%) |
May 12, 2026 24w ago | Press Release | $4.28 $4.22 | ▼ −1.40% | ▼ −5.84% | $1.98 (−53.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers